Kunyao Group

KPC Pharmaceuticals, also known as Kunyao Group, is a prominent Chinese pharmaceutical company specializing in the research, development, and manufacturing of plant-based medicines and chemical drugs. Founded in 1951 and headquartered in Kunming, Yunnan, the company is globally recognized for its pioneering role in artemisinin-based anti-malarial treatments and Panax notoginseng-derived cardiovascular therapies. KPC operates a vertically integrated business model that includes raw material cultivation, advanced R&D, and international commercialization. Recently integrated into the China Resources (CR) Sanjiu ecosystem, the company is strategically focusing on traditional Chinese medicine (TCM) and chronic disease management for the aging population. Their product portfolio includes well-known brands such as Xuesaitong and various artemisinin derivatives.